



McKesson Cancer Care Survey

A Nationally Representative Survey Conducted by Ipsos

Washington, DC, September 25, 2018 –

1. What qualities of healthcare are the most important to you?

	Total (N = 2,012)
Experienced/knowledgeable providers	58%
Affordability	56%
A high level of personal interaction and support of staff/provider	20%
Proximity of hospital / treatment center	18%
Access to latest technologies	16%
Respect of provider	9%
Access to novel therapies / clinical trials	3%
Other	1%
Don't know	4%

2. How worried are you about being diagnosed with cancer?

	Total
Very worried	14%
Somewhat worried	33%
Not very worried	34%
Not at all worried	14%
Don't know	4%
Worried (Net)	48%
Not worried (Net)	48%

Address: 2020 K Street NW, Suite 410
Washington, DC 20006
Tel: +1 202 463-7300

Contact: **Nicolas Boyon**
Senior Vice President, U.S., Ipsos Public Affairs
Email: nicolas.boyon@ipsos.com
Tel: +1 646 309 4879



Press Release – continued –

3. Which of the following are you most worried about in case you were diagnosed with cancer?

People worried about being diagnosed with cancer	Total (N = 973)
Dying	30%
Being a burden to family members	23%
Cost of treatment	17%
Suffering/enduring pain	17%
Finding quality treatment	9%
No longer being able to work	4%
Other	1%

4. If I were diagnosed with cancer, I am concerned that...

	I would not be able to afford treatment	It would have a catastrophic impact on my finances	I would not be able to receive quality treatment
Strongly agree	34%	47%	21%
Somewhat agree	28%	28%	28%
Somewhat disagree	20%	13%	28%
Strongly disagree	12%	7%	18%
Don't know	6%	5%	6%
Agree (Net)	62%	75%	49%
Disagree (Net)	32%	21%	46%

5. How much of your cancer treatment do you think would be covered by your health insurance?

	Total
All of it	13%
Most of it	35%
Some of it	42%
None of it	3%
I don't have health insurance	7%

Address: 2020 K Street NW, Suite 410
Washington, DC 20006
Tel: +1 202 463-7300

Contact: **Nicolas Boyon**
Senior Vice President, U.S., Ipsos Public Affairs
Email: nicolas.boyon@ipsos.com
Tel: +1 646 309 4879



Press Release – continued –

6. For which of the following reasons would you possibly forgo cancer treatment?

	Total
Cost of treatment	42%
Belief that treatment won't help	34%
Fear of treatment	13%
Lack of access to care	13%
Lack of transportation to a treatment center	4%
Other	3%
I would never forgo treatment	30%

7. What financial resources do you have in the event that you would need to take time off from work?

People who are employed	Total (N = 1,155)
Family support	42%
Employer-sponsored disability insurance	38%
Sufficient savings	28%
Personal life/disability insurance	26%
Long-term disability insurance/government assistance	22%
Other	2%
None of the above	20%

8. If you were diagnosed with cancer, how much confidence do you have that you would be able to receive quality cancer care?

	Total
Very confident	27%
Somewhat confident	45%
Not very confident	14%
Not confident at all	7%
I don't know	7%
Confident (Net)	72%
Not confident (Net)	21%

Address: 2020 K Street NW, Suite 410
Washington, DC 20006
Tel: +1 202 463-7300

Contact: **Nicolas Boyon**
Senior Vice President, U.S., Ipsos Public Affairs
Email: nicolas.boyon@ipsos.com
Tel: +1 646 309 4879



Press Release – continued –

9. Which of the following do you believe is the biggest barrier to receiving quality cancer care?

	Total
The cost of treatment is too high	46%
Insurance coverage of treatment is insufficient	32%
Quality of cancer treatment facilities in my area is poor	10%
Not enough doctors and other providers in my area	7%
Other	5%

10. How much progress do you believe the healthcare industry has made in curing cancer over the past decade?

	Total
A great deal of progress	17%
A fair amount of progress	29%
Some progress	30%
Not much progress	15%
No progress at all	3%
Don't know	6%

11. How likely is it that there will be a cure for cancer within 50 years?

	Total
Very likely	23%
Somewhat likely	38%
Somewhat unlikely	16%
Very unlikely	11%
Don't know	12%
Likely (Net)	61%
Unlikely (Net)	27%

12. Would you consider using a DNA/genetic test to assess your risk for cancer?

	Total
Yes, definitely	24%
Yes, probably	36%
No, probably not	21%
No, definitely not	6%
Not sure	13%
Yes (Net)	60%
No (Net)	27%

Address: 2020 K Street NW, Suite 410
Washington, DC 20006
Tel: +1 202 463-7300

Contact: **Nicolas Boyon**
Senior Vice President, U.S., Ipsos Public Affairs
Email: nicolas.boyon@ipsos.com
Tel: +1 646 309 4879



Press Release – continued –

13. Why not?

People who would not use DNA/genetic testing	Total (N = 819)
I would not want to know	27%
Not interested	21%
Privacy concerns	20%
Too expensive	15%
Not effective	8%
I don't know enough to say	25%

14. Would you trust artificial intelligence technology to diagnose you or recommend a course of cancer treatment?

	Total
Yes, definitely	9%
Yes, probably	35%
No, probably not	26%
No, definitely not	9%
Not sure	21%
Yes (Net)	44%
No (Net)	35%

15. If you were diagnosed with cancer, how important to you would each of the following be when choosing a cancer provider or treatment?

	Cost of treatment / insurance coverage	Access to latest technologies / novel therapies / clinical trials	Personal interaction and support from staff/providers	Well-known facility
Extremely important	46%	37%	32%	24%
Very important	31%	37%	42%	36%
Somewhat important	17%	19%	21%	29%
Not very important	3%	2%	2%	6%
Not important at all	1%	1%	1%	2%
Don't know	2%	3%	2%	2%
Important (Net)	77%	75%	74%	60%
Not important (Net)	4%	3%	3%	8%

Address: 2020 K Street NW, Suite 410
Washington, DC 20006
Tel: +1 202 463-7300

Contact: **Nicolas Boyon**
Senior Vice President, U.S., Ipsos Public Affairs
Email: nicolas.boyon@ipsos.com
Tel: +1 646 309 4879



Press Release – continued –

	Proximity to my home	Word of mouth / recommendation from family or friends	Prior experience with the facility	(If employed) Proximity to work
Extremely important	19%	14%	13%	10%
Very important	33%	26%	22%	17%
Somewhat important	34%	39%	30%	34%
Not very important	7%	13%	22%	24%
Not important at all	3%	4%	7%	12%
Don't know	2%	4%	5%	3%
Important (Net)	53%	40%	35%	27%
Not important (Net)	11%	17%	29%	36%

Address: 2020 K Street NW, Suite 410
Washington, DC 20006
Tel: +1 202 463-7300

Contact: **Nicolas Boyon**
Senior Vice President, U.S., Ipsos Public Affairs
Email: nicolas.boyon@ipsos.com
Tel: +1 646 309 4879



Press Release – continued –

About the Study

These are findings from an Ipsos poll conducted August 20-22, 2018, on behalf of McKesson Corporation. For the survey, a sample of 2,012 adults 18+ from the continental U.S., Alaska and Hawaii were interviewed online in English.

The sample for this study was randomly drawn from Ipsos' online panel (see link below for more info on "Access Panels and Recruitment"), partner online panel sources, and "river" sampling (see link below for more info on the Ipsos "Ampario Overview" sample method) and does not rely on a population frame in the traditional sense. Ipsos uses fixed sample targets, unique to each study, in drawing a sample. After a sample has been obtained from the Ipsos panel, Ipsos calibrates respondent characteristics to be representative of the U.S. Population using standard procedures such as raking-ratio adjustments. The source of these population targets is U.S. Census 2013 American Community Survey data. The sample drawn for this study reflects fixed sample targets on demographics. Post-hoc weights were made to the population characteristics on gender, age, race/ethnicity, region, and education.

Statistical margins of error are not applicable to online polls. All sample surveys and polls may be subject to other sources of error, including, but not limited to coverage error and measurement error. Where figures do not sum to 100, this is due to the effects of rounding. The precision of Ipsos online polls is measured using a credibility interval. In this case, the poll has a credibility interval of plus or minus 2.5 percentage points for all respondents. Ipsos calculates a design effect (DEFF) for each study based on the variation of the weights, following the formula of Kish (1965). This study had a credibility interval adjusted for design effect of the following (n=2,009, DEFF=1.5, adjusted Confidence Interval=+/-4 percentage points).

For more information about conducting research intended for public release or Ipsos' online polling methodology, please visit our [Public Opinion Polling and Communication](#) page where you can download our brochure, see our public release protocol, or contact us.

Address: 2020 K Street NW, Suite 410
Washington, DC 20006
Tel: +1 202 463-7300

Contact: **Nicolas Boyon**
Senior Vice President, U.S., Ipsos Public Affairs
Email: nicolas.boyon@ipsos.com
Tel: +1 646 309 4879



Press Release – continued –

About Ipsos Public Affairs

Ipsos Public Affairs is a non-partisan, objective, survey-based research practice made up of seasoned professionals. We conduct strategic research initiatives for a diverse number of American and international organizations, based not only on public opinion research, but elite stakeholder, corporate, and media opinion research.

Ipsos has media partnerships with the most prestigious news organizations around the world. Through our media partnerships, Ipsos Public Affairs is a leading source of intelligent information for businesses and professionals in the U.S., Canada, the UK, and internationally. Ipsos Public Affairs is a member of the Ipsos Group, a leading global survey-based market research company. We provide boutique-style customer service and work closely with our clients, while also undertaking global research.

About Ipsos

Ipsos is an independent market research company controlled and managed by research professionals. Founded in France in 1975, Ipsos has grown into a worldwide research group with a strong presence in all key markets. Ipsos ranks fourth in the global research industry.

With offices in 88 countries, Ipsos delivers insightful expertise across five research specializations: brand, advertising and media; customer loyalty; marketing; public affairs research; and survey management.

Ipsos researchers assess market potential and interpret market trends. They develop and build brands. They help clients build long-term relationships with their customers. They test advertising and study audience responses to various media and they measure public opinion around the globe.

Ipsos has been listed on the Paris Stock Exchange since 1999 and generated global revenues of €1,782.7 million in 2016.

GAME CHANGERS

« Game Changers » is the Ipsos signature.

At Ipsos we are passionately curious about people, markets, brands and society.
We make our changing world easier and faster to navigate and inspire clients to make smarter decisions.
We deliver with security, speed, simplicity and substance. We are Game Changers.

Ipsos is listed on Eurolist – NYSE-Euronext.
The company is part of the SBF 120 and the Mid-60 index
and is eligible for the Deferred Settlement Service (SRD).

ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP
www.ipsos.com

Address: 2020 K Street NW, Suite 410
Washington, DC 20006
Tel: +1 202 463-7300

Contact: **Nicolas Boyon**
Senior Vice President, U.S., Ipsos Public Affairs
Email: nicolas.boyon@ipsos.com
Tel: +1 646 309 4879